Navigo Proteins GmbH announced a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, that will focus on the preclinical development of next-generation radiotheranostics, using the Auger-electron emitting radioisotope Terbium (¹⁶¹Tb).

The partnership will leverage Navigo Proteins’ Affilin and HEAD platforms and knowledge of radiotheranostic development with SCK CEN’s expertise in radioisotopes. The two organizations aim to accelerate the development of radioligand therapies—highly specific, targeted therapies for cancer patients.

The collaboration will focus on preclinical studies of multiple undisclosed targets using radiotheranostic approaches. Researchers will test these molecules to deliver the radioactivity to tumors and assess their efficiency. The aim is to identify a candidate within two to three years and prepare all necessary data to initiate clinical studies.

“Navigo Proteins and SCK CEN each have extensive experience in key ingredients of radiopharmaceuticals. Navigo has developed carrier molecules, while SCK CEN provides terbium-161, infrastructure, and expertise in preclinical testing. Combining these complementary strengths saves valuable development time,” commented, Koen Hasaers, Director of Nuclear Medical Applications at SCK CEN.